mobile navigation
TIRN logo
mobile navigation

Transplantation and Immunology Research Network

american society of transplantation

News

In Memoriam: Daniel R. Salomon, MD

November 16, 2016

It is with heavy hearts that we share the sad news of the recent passing of Dan Salomon. As president of the AST from 2013-2014, Dan's contributions to the Society were quite visionary. Read his tribute, written by Ken Newell, on the AST website.

Read the tribute here


AST Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding

July 28, 2014

The American Society of Transplantation (AST), representing the majority of professionals engaged in the field of organ transplantation, today announced the launch of the Transplantation and Immunology Research Network (TIRN), a professional network established to advance transplantation and immunology research. As modern organ transplantation continues to diversify, AST determined the field needed a network that could provide more opportunities for physicians, scientists and researchers to collaborate within their respective specialty areas and engage those interested in funding groundbreaking research. TIRN was thus established as a means to support basic, translational and clinical research in transplantation and immunology by bringing together investigators, research partners, patients and the general public. The announcement was made at the 2014 World Transplant Congress in San Francisco, an event which itself represents the cooperation necessary for driving innovation in transplantation and immunology research.

TIRN will provide opportunities for researchers to learn from one another by building on their collective strengths, expanding their knowledge of cutting-edge techniques, and growing their professional connections. This new network includes industry leaders, private organizations and academic institutions that support transplantation research and are committed to nurturing the next generation of investigators. Patients and their families along with the general public will also be able to better understand the positive impact of new research.

“Advancing research is a critical step towards improving human life,” said Daniel R. Salomon, MD, TIRN chair and outgoing AST president. “Our vision is to establish TIRN as a collaborative network of innovators, people that will be responsible for developing the next generation of medications, tests and technical advances in our industry. We must come together to support research that will not only advance organ transplantation, but all areas of science and medicine.”

Like AST, TIRN will be governed by a committee of experts in transplantation and immunology. The committee will be appointed by the AST President, and approved by the AST Board of Directors.

Since 1995, AST has funded more than 200 research projects with more than $10 million through its existing research grants funding structure. This funding has spurred innovative research that has dramatically enhanced the field of organ transplantation. TIRN is currently accepting applications for grant funding for research with priorities in the areas of basic science, clinical science and translational science. Investigators are encouraged to apply for funding at www.TIRN.org by Sept. 15, 2014.

For more information on joining TIRN or becoming a TIRN industry partner, please visit www.TIRN.org.

About The American Society of Transplantation (AST): The American Society of Transplantation (AST) is an international organization of transplant professionals who are dedicated to advancing the field of transplantation and improving patient care by promoting research, education, advocacy, and organ donation. The Society comprises more than 3,300 transplant physicians, surgeons, scientists and allied health professionals. For more information about the Society, go to www.myAST.org.


AST President Featured in USA Today Supplement on Organ Transplantation

June 15, 2014

American Society of Transplantation (AST) President Daniel R. Salomon, MD was recently interviewed by Mediaplanet, the developer of an independent supplement to USA Today which focused on organ transplantation. Dr. Salomon discusses the current prognosis for organ transplant recipients, and explains how the creation of AST's Transplantation and Immunology Research Network (TIRN) can help improve that prognosis by supporting innovative research in the field.

Read the full article here


AST Supports Congressional 21st Century Cures Initiative

June 4, 2014

The American Society of Transplantation (AST) is dedicated to advancing the future of transplant research, which spurred the development of the Transplantation and Immunology Research Network (TIRN). AST is proud to support the House Energy and Commerce Chairman's 21st Century Cures Initiative, which aims to accelerate medical research to develop new cures and treatments for patients across the country. Read AST's letter to Congresswoman Diana DeGette, and Congressman Fred Upton, Chairman of the Energy & Commerce Committee.

The primary goal of the initiative is to accelerate the pace of the discovery, development, and delivery cycle so that patients can get innovative new cures and treatments more quickly.

Our nation's biomedical innovation ecosystem is under significant stress, citing the patent cliff facing the pharmaceutical industry, declining investment from venture capital, and decreasing research and development in critical areas. In order to address these issues, the experts who contributed to the report recommend closing scientific knowledge gaps, addressing inefficiencies in clinical trials, considering new economic incentives to increase investment, and encouraging even more innovation at the Food and Drug Administration.

President Obama's advisors put forth the following goal: "Double the current annual output of innovative new medicines for patients with important unmet medical needs, while increasing drug efficacy and safety, through industry, academia, and government working together to double the efficiency of drug development, by decreasing clinical failure, clinical trial costs, time to market, and regulatory uncertainty."

The 21st Century Cures Initiative ultimately touches everyone - patients, doctors, researchers, thought leaders. Email your ideas to cures@mail.house.gov and contribute to the conversation on Twitter and Facebook using the hashtag #Path2Cures.